These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1423177)

  • 41. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
    Pritchard KI; Paterson AH; Fine S; Paul NA; Zee B; Shepherd LE; Abu-Zahra H; Ragaz J; Knowling M; Levine MN; Verma S; Perrault D; Walde PL; Bramwell VH; Poljicak M; Boyd N; Warr D; Norris BD; Bowman D; Armitage GR; Weizel H; Buckman RA
    J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer.
    Rutqvist LE; Cedermark B; Glas U; Johansson H; Rotstein S; Skoog L; Somell A; Theve T; Wilking N; Askergren J
    Cancer; 1990 Jul; 66(1):89-96. PubMed ID: 2191764
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01).
    Belfiglio M; Valentini M; Pellegrini F; De Berardis G; Franciosi M; Rossi MC; Sacco M; Nicolucci A;
    Cancer; 2005 Dec; 104(11):2334-9. PubMed ID: 16245354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
    Gelber RD; Cole BF; Goldhirsch A; Rose C; Fisher B; Osborne CK; Boccardo F; Gray R; Gordon NH; Bengtsson NO; Sevelda P
    Lancet; 1996 Apr; 347(9008):1066-71. PubMed ID: 8602056
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of postoperative adjuvant therapy for stage ilia breast cancer: Futraful vs futraful+tamoxifen for ER-positive patients and futraful vs futraful + adriamycin for ER-negative breast cancer.
    Yoshida M; Abe O; Uchino J; Kikuchi K; Abe R; Enomoto K; Tominaga T; Fukami A; Sakai K; Koyama H; Sugimachi K; Nomura Y; Hattori T; Ogawa N
    Breast Cancer; 1997; 4(2):103-13. PubMed ID: 18843555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Post-operative Adjuvant Therapy for Stage IIIa Berast Cancer: Futraful vs Futraful+Tamoxifen for ER-positive Patients and Futraful vs Futraful+Adriamycin for ER-negative Breast Cancer.
    Yoshida M; Abe O; Uchino J; Kikuchi K; Abe R; Enomoto K; Tominaga T; Fukami A; Sakai K; Koyama H; Sugimachi K; Nomura Y; Hattori T; Ogawa N
    Breast Cancer; 1997 Jul; 4(2):103-113. PubMed ID: 11091584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
    International Breast Cancer Study Group
    J Clin Oncol; 1997 Apr; 15(4):1385-94. PubMed ID: 9193330
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvant hormone treatment and chemotherapy in postmenopausal women with operable breast cancer: a retrospective analysis.
    Oriana S; Coradini D; Sasso GM; Di Fronzo G
    Anticancer Res; 1991; 11(6):2199-205. PubMed ID: 1776861
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Cooperative research on post-operative adjuvant therapy of breast cancer. Tohoku Society of Adjuvant Chemo-endocrine Therapy of Breast Cancer].
    Abe R; Tsuchiya A; Koie H; Ono K; Abo S; Saito K; Tsukamoto M; Sato T; Mori S; Motoki R
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2707-12. PubMed ID: 3137888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer. Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer.
    Sakai K; Kosaki G; Seno T; Taguchi T; Terasawa T; Nakao K; Koyama H; Oshima A
    Cancer Chemother Pharmacol; 1996; 37(6):587-92. PubMed ID: 8612314
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.
    Fisher B; Redmond C; Brown A; Fisher ER; Wolmark N; Bowman D; Plotkin D; Wolter J; Bornstein R; Legault-Poisson S
    J Clin Oncol; 1986 Apr; 4(4):459-71. PubMed ID: 2856857
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.
    Blomqvist C; Tiusanen K; Elomaa I; Rissanen P; Hietanen T; Heinonen E; Gröhn P
    Br J Cancer; 1992 Dec; 66(6):1171-6. PubMed ID: 1457360
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
    J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
    Tormey DC; Gray R; Falkson HC
    J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
    Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
    Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
    Makris A; Powles TJ; Dowsett M; Osborne CK; Trott PA; Fernando IN; Ashley SE; Ormerod MG; Titley JC; Gregory RK; Allred DC
    Clin Cancer Res; 1997 Apr; 3(4):593-600. PubMed ID: 9815725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.